Vivacitas was co-founded in 2015 by Dr. Rubinfeld with an eye toward re-designing well known chemotherapies that have already been demonstrated to have beneficial effects, but which may also possess potency, toxicity, stability and/or pharmacokinetic issues that limit their use. To this end, the Company has been laser-focused on acquiring its 3 mature pipeline assets, made possible by leveraging the extraordinary professional network that 'Dr. Joe' fostered over a lifetime in the industry. As a result, Vivacitas was able to complete the acquisitions of its 3 major programs within a 12-month period.

Contributing to the impressive asset acquisition track record is Vivacitas' close partnership with International Infusion Advisors, LLC via its investment arm, Infusion 51A, a relationship that is anchored in a common mission - to develop disruptive technologies aimed at improving the quality of life of cancer patients.